Author:
Esposito Susanna,Terranova Leonardo,Patria Maria Francesca,Marseglia Gian Luigi,Miraglia del Giudice Michele,Bodini Alessandro,Martelli Alberto,Baraldi Eugenio,Mazzina Oscar,Tagliabue Claudia,Licari Amelia,Ierardi Valentina,Lelii Mara,Principi Nicola
Funder
Italian Ministry of Health
Pfizer International
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000;49(RR-9):1–35.
2. Esposito S, Musio A, Principi N. Paediatric asthma and pneumococcal vaccination. Vaccine. 2013;31:5015–9.
3. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62:521–4.
4. Mitchell R, Trück J, Pollard AJ. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6–17 years. Expert Opin Biol Ther. 2013;13:1451–65.
5. Veenhoven RH, Bogaert D, Schilder AG, Rijkers GT, Uiterwaal CS, van Kempen MJ, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clin Infect Dis. 2004;39:911–9.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献